JPWO2022013136A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022013136A5 JPWO2022013136A5 JP2023502631A JP2023502631A JPWO2022013136A5 JP WO2022013136 A5 JPWO2022013136 A5 JP WO2022013136A5 JP 2023502631 A JP2023502631 A JP 2023502631A JP 2023502631 A JP2023502631 A JP 2023502631A JP WO2022013136 A5 JPWO2022013136 A5 JP WO2022013136A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyridin
- dihydro
- piperazin
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/101904 | 2020-07-14 | ||
| CN2020101904 | 2020-07-14 | ||
| CN2021094138 | 2021-05-17 | ||
| CNPCT/CN2021/094138 | 2021-05-17 | ||
| PCT/EP2021/069294 WO2022013136A1 (en) | 2020-07-14 | 2021-07-12 | Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023533807A JP2023533807A (ja) | 2023-08-04 |
| JP2023533807A5 JP2023533807A5 (https=) | 2024-07-22 |
| JPWO2022013136A5 true JPWO2022013136A5 (https=) | 2024-07-22 |
Family
ID=77126791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023502631A Ceased JP2023533807A (ja) | 2020-07-14 | 2021-07-12 | 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240317735A1 (https=) |
| EP (1) | EP4182032A1 (https=) |
| JP (1) | JP2023533807A (https=) |
| CN (1) | CN115835910A (https=) |
| TW (1) | TW202216711A (https=) |
| WO (1) | WO2022013136A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4196222A1 (en) * | 2020-08-14 | 2023-06-21 | Minerva Neurosciences, Inc. | Condensed azacycles as sigma ligand compounds and uses thereof |
| PE20250401A1 (es) * | 2021-09-24 | 2025-02-11 | Hoffmann La Roche | Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades auto/inmunitarias |
| CN120230100B (zh) * | 2025-05-30 | 2025-09-05 | 中国药科大学 | 一种咪唑并[1,2-a]吡嗪或咪唑并[1,2-a]吡啶类化合物及其医药用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013032290A (ja) * | 2009-11-20 | 2013-02-14 | Dainippon Sumitomo Pharma Co Ltd | 新規縮合ピリミジン誘導体 |
| JP6306750B2 (ja) | 2014-03-07 | 2018-04-04 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂ型肝炎ウイルス感染症の治療および予防のための新規な６−縮合ヘテロアリールジヒドロピリミジン |
| HRP20220144T1 (hr) * | 2016-09-09 | 2022-04-15 | Novartis Ag | Spojevi i pripravci kao inhibitori endosomskih toll-u sličnih receptora |
| WO2018218197A2 (en) * | 2017-05-26 | 2018-11-29 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| EP3728218B1 (en) * | 2017-12-20 | 2021-12-01 | Bristol-Myers Squibb Company | Amino indole compounds useful as tlr inhibitors |
| JP7407740B2 (ja) | 2018-05-18 | 2024-01-04 | ノバルティス アーゲー | Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態 |
| EP3802539B1 (en) | 2018-06-05 | 2023-09-20 | F. Hoffmann-La Roche AG | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease |
| MX2021012223A (es) * | 2019-04-09 | 2021-11-03 | Hoffmann La Roche | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria. |
-
2021
- 2021-07-12 US US18/016,289 patent/US20240317735A1/en active Pending
- 2021-07-12 EP EP21748533.3A patent/EP4182032A1/en active Pending
- 2021-07-12 CN CN202180049160.3A patent/CN115835910A/zh active Pending
- 2021-07-12 JP JP2023502631A patent/JP2023533807A/ja not_active Ceased
- 2021-07-12 WO PCT/EP2021/069294 patent/WO2022013136A1/en not_active Ceased
- 2021-07-13 TW TW110125634A patent/TW202216711A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112166110B (zh) | Shp2磷酸酶抑制剂及其使用方法 | |
| EP3630770B1 (en) | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors | |
| US20240245681A1 (en) | Heterocyclic derivatives useful as shp2 inhibitors | |
| JP6631616B2 (ja) | ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用 | |
| JPWO2020081848A5 (https=) | ||
| JP2022543689A (ja) | Ｓｈｐ２阻害剤 | |
| AU2021376415A1 (en) | Brm targeting compounds and associated methods of use | |
| TW202423440A (zh) | Ｋｒａｓ ｇ１２ｃ突變蛋白的系鏈之雜環抑制劑及其用途 | |
| JP2020522570A (ja) | ハンチントン病を処置するための化合物 | |
| JP2020522570A5 (https=) | ||
| JP2015504057A5 (https=) | ||
| JP2014506929A5 (https=) | ||
| JPWO2019191092A5 (https=) | ||
| US20240182465A1 (en) | Fused ring substituted six-membered heterocyclic compound, preparation method therefor and use thereof | |
| JP2025538097A (ja) | がんを処置するための方法 | |
| JP2024540912A (ja) | 癌の治療における使用のためのヘテロ環式化合物 | |
| TW202104230A (zh) | 用於治療自體免疫疾病之六氫-1H-吡并[1,2-a]吡化合物 | |
| JP2023502087A (ja) | 自己免疫疾患の処置のためのヒドロ－１Ｈ－ピロロ［１，２－ａ］ピラジン化合物 | |
| JPWO2019233941A5 (https=) | ||
| JPWO2022013136A5 (https=) | ||
| CN112673007A (zh) | 用于治疗自身免疫性疾病的吡唑并吡啶胺化合物 | |
| JPWO2020207991A5 (https=) | ||
| TW202330525A (zh) | 稠環取代的六員雜環化合物及其製法和用途 | |
| RU2020142969A (ru) | СОЕДИНЕНИЯ ТЕТРАГИДРО-1Н-ПИРАЗИНО[2,1- a]ИЗОИНДОЛИЛХИНОЛИНА ДЛЯ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ | |
| NZ771342B2 (en) | Heteroaryl compounds for treating huntington's disease |